Precigen (NASDAQ:PGEN) COO Rutul Shah Sells 15,342 Shares of Stock

Precigen, Inc. (NASDAQ:PGEN) COO Rutul Shah sold 15,342 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $7.50, for a total value of $115,065.00. Following the completion of the sale, the chief operating officer directly owned 468,865 shares of the company’s stock, valued at approximately $3,516,487.50. This trade represents a 3.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Precigen Price Performance

PGEN opened at $7.28 on Wednesday. The stock’s 50 day simple moving average is $5.91 and its 200 day simple moving average is $4.69. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 3.89. Precigen, Inc. has a 1 year low of $2.99 and a 1 year high of $7.55. The firm has a market cap of $2.60 billion, a price-to-earnings ratio of -7.00 and a beta of 1.02.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. The business had revenue of $54.98 million for the quarter, compared to analysts’ expectations of $27.98 million. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The firm’s revenue for the quarter was up 6322.7% compared to the same quarter last year. As a group, analysts predict that Precigen, Inc. will post 0.25 earnings per share for the current year.

Institutional Trading of Precigen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Wyoming bought a new position in Precigen in the 1st quarter worth $27,000. NBC Securities Inc. purchased a new stake in shares of Precigen in the 4th quarter worth about $38,000. Mason Investment Advisory Services Inc. bought a new stake in shares of Precigen during the 4th quarter valued at about $42,000. Abel Hall LLC bought a new stake in shares of Precigen during the 4th quarter valued at about $44,000. Finally, Royal Bank of Canada increased its position in shares of Precigen by 102.6% during the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,426 shares during the period. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Key Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong PAPZIMEOS sales and quarterly profitability: Precigen reported that PAPZIMEOS generated $53.1 million in second-quarter net product revenue, more than double the previous quarter. The company said the performance marked a commercial inflection point and helped it achieve quarterly profitability, supporting the stock’s upward momentum. Precigen’s Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform
• Positive Sentiment: Pipeline progress adds to the investment case: PRGN-2009 is advancing in HPV-driven cancers, while management highlighted the broader potential of its AdenoVerse therapeutic platform. The combination of commercial revenue and pipeline development is reinforcing expectations for further growth. Precigen’s Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform
• Positive Sentiment: New 1-year high: PGEN reached a new 52-week high, signaling strong recent trading momentum as investors responded to the company’s improved operating performance. Precigen Reaches New 1-Year High
• Positive Sentiment: Director purchase: Director Nancy H. Agee bought 3,411 shares at an average price of $7.23, modestly increasing her ownership. The purchase may be viewed as a sign of confidence in Precigen’s outlook.
• Neutral Sentiment: COO share sales were tax-related: COO Rutul R. Shah sold a combined 50,000 shares at approximately $7.50 under a pre-arranged Rule 10b5-1 plan to cover tax withholding tied to vested equity awards. Because the sales were planned and administrative, they provide limited bearish information, although they reduce his holdings.
• Neutral Sentiment: Short-interest data is inconclusive: Reported short interest was zero, making the published change and short-interest ratio unreliable as indicators of investor positioning.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on PGEN shares. Wall Street Zen raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Zacks Research raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 5th. Citigroup reiterated an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. Finally, Citizens Jmp boosted their price target on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $14.50.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.